Luis Pareras
Gründer bei Invivo Capital Partners SGEIC SA
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Albert Ferrer Olivera | M | - |
Invivo Capital Partners SGEIC SA
 Invivo Capital Partners SGEIC SA Investment ManagersFinance Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain.
Gyala Therapeutics SL
 Gyala Therapeutics SL BiotechnologyHealth Technology Gyala Therapeutics SL develops CAR-T therapies for treating hematological malignancies. The company is based in Barcelona, Spain. Claudio Santos has been the CEO of the Spanish company since 2020.
Pulmobiotics SL
 Pulmobiotics SL BiotechnologyHealth Technology Pulmobiotics SL operates as a spin off company. The firm uses its technology to discover and develop novel treatments and vaccines for respiratory diseases. The company was founded by Maria Lluch and Lluis Serrano and is headquartered in Barcelona, Spain.
Telum Therapeutics SL
 Telum Therapeutics SL Miscellaneous Commercial ServicesCommercial Services Telum Therapeutics SL is a Spanish biotechnology company that specializes in drug discovery and the use of Innovative Phage Lytic Proteins as antibiotics. The company is based in Noáin, Spain. The company has specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. The CEO of the company is Roberto Díez-Martínez. | 5 Jahre |
| Roberto Díez-Martínez | M | - |
Telum Therapeutics SL
Telum Therapeutics SL Miscellaneous Commercial ServicesCommercial Services Telum Therapeutics SL is a Spanish biotechnology company that specializes in drug discovery and the use of Innovative Phage Lytic Proteins as antibiotics. The company is based in Noáin, Spain. The company has specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. The CEO of the company is Roberto Díez-Martínez. | - |
| Maria Lluch | M | - |
Pulmobiotics SL
Pulmobiotics SL BiotechnologyHealth Technology Pulmobiotics SL operates as a spin off company. The firm uses its technology to discover and develop novel treatments and vaccines for respiratory diseases. The company was founded by Maria Lluch and Lluis Serrano and is headquartered in Barcelona, Spain. | - |
| Claudio Santos | M | - |
Pulmobiotics SL
Pulmobiotics SL BiotechnologyHealth Technology Pulmobiotics SL operates as a spin off company. The firm uses its technology to discover and develop novel treatments and vaccines for respiratory diseases. The company was founded by Maria Lluch and Lluis Serrano and is headquartered in Barcelona, Spain. | - |
| Gemma Guinart | F | - |
Invivo Capital Partners SGEIC SA
Invivo Capital Partners SGEIC SA Investment ManagersFinance Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain. | 4 Jahre |
| Santiago Lozano Manterola | M | 51 |
Telum Therapeutics SL
Telum Therapeutics SL Miscellaneous Commercial ServicesCommercial Services Telum Therapeutics SL is a Spanish biotechnology company that specializes in drug discovery and the use of Innovative Phage Lytic Proteins as antibiotics. The company is based in Noáin, Spain. The company has specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. The CEO of the company is Roberto Díez-Martínez. | - |
| Alberto Carrasco | M | - |
Invivo Capital Partners SGEIC SA
Invivo Capital Partners SGEIC SA Investment ManagersFinance Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain. | 5 Jahre |
| Rubén Díez Punzano | M | - |
Telum Therapeutics SL
Telum Therapeutics SL Miscellaneous Commercial ServicesCommercial Services Telum Therapeutics SL is a Spanish biotechnology company that specializes in drug discovery and the use of Innovative Phage Lytic Proteins as antibiotics. The company is based in Noáin, Spain. The company has specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. The CEO of the company is Roberto Díez-Martínez. | - |
| Laura Rodriguez Gallego | F | - |
Invivo Capital Partners SGEIC SA
Invivo Capital Partners SGEIC SA Investment ManagersFinance Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain. | 6 Jahre |
| Oscar Ferrer | M | - |
Invivo Capital Partners SGEIC SA
Invivo Capital Partners SGEIC SA Investment ManagersFinance Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain. | 5 Jahre |
| Jesús M. Hernandez | M | - |
Telum Therapeutics SL
Telum Therapeutics SL Miscellaneous Commercial ServicesCommercial Services Telum Therapeutics SL is a Spanish biotechnology company that specializes in drug discovery and the use of Innovative Phage Lytic Proteins as antibiotics. The company is based in Noáin, Spain. The company has specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. The CEO of the company is Roberto Díez-Martínez. | - |
| Rosa Vilavella | F | - |
Gyala Therapeutics SL
Gyala Therapeutics SL BiotechnologyHealth Technology Gyala Therapeutics SL develops CAR-T therapies for treating hematological malignancies. The company is based in Barcelona, Spain. Claudio Santos has been the CEO of the Spanish company since 2020. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Charlie Hill-Wood | M | - |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Luka Podlogar | M | - |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| María Dolores Castillo García | F | - |
Instituto de Estudios Superiores de la Empresa
| 1 Jahre |
| David Oses | M | - |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Francisco Joao di Mase Galvao | M | 43 |
Instituto de Estudios Superiores de la Empresa
| 4 Jahre |
| Baldur Stefansson | M | - |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Matthias Bulach | M | 48 |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Fernando de Lapuerta Montoya | M | 47 |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Nico De Waal | M | - |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Dianne Lisette Sandoval | F | - |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Tobias Thelen | M | 48 |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| José Lopez Portillo | M | - |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Luís Manuel Palma da Graça | M | - |
Instituto de Estudios Superiores de la Empresa
| 1 Jahre |
| Miguel Rodrigo Doménech Martínez | M | - |
Instituto de Estudios Superiores de la Empresa
| - |
| Erna Gísladóttir | F | 56 |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Erik Koch Boyter | M | 57 |
Instituto de Estudios Superiores de la Empresa
| 1 Jahre |
| Hendrik Jan ten Have | M | - |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Dariusz Jacek Blocher | M | 57 |
Instituto de Estudios Superiores de la Empresa
| 4 Jahre |
| Timo Bütefisch | M | - |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Igor Vladimirovich Bulantsev | M | 55 |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Pablo Pío Giménez Soriano | M | - |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
| Paul Artigas | M | - |
Instituto de Estudios Superiores de la Empresa
| 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Spanien | 34 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Luis Pareras
- Persönliches Netzwerk
